Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In situ cancer vaccines exploiting endogenous multiple antigens directly from tumors to elicit broad immune responses hold great potential in cancer treatment. However, the feeble antigen presentation and hostile immune microenvironments pose severe challenges to acquiring clinical benefits. Here, oncolytic STING-activating microgels (OSAM) that release oncolytic peptide LTX-315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long-acting and powerful antitumor immunity. OSAM induced significant upregulation of MHC I and substantial activation of dendritic cells for more than one week. One single intratumoral administration of OSAM markedly promoted the infiltration of cytotoxic T lymphocytes and natural killer cells, which combining with anti-CTLA-4 microgels afforded exceptional therapeutic benefits in several different murine tumor models with a cure rate of 40%-71%. These oncolytic STING-activating microgels introduce a new and powerful strategy to in situ cancer vaccines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/smll.202503561 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lineage Switch of Adult B-Cell Acute Lymphoblastic Leukaemia to Acute Myeloid Leukaemia Following B-Cell-Directed Therapy.
Eur J Case Rep Intern Med
August 2025
Division of Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA.
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.
View Article and Find Full Text PDFPhotoacoustic-imaging nanomotors enhance tumor penetration and alleviate hypoxia for photodynamic therapy of breast cancer.
Biomater Sci
September 2025
Key Laboratory for Organic Electronics and Information Displays and Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials, Jiangsu National Synergetic Innovation Centre for Advanced Materials, Nanjing University of Posts and Telecommunications, Nanjing 210023, P.R. China. iamzgteng@
Breast cancer is the most prevalent malignancy worldwide, yet conventional therapies are invasive and prone to resistance, recurrence, and metastasis. Photodynamic therapy (PDT) is a promising noninvasive modality, but its efficacy is limited by tumor hypoxia and poor photosensitizer delivery. Here, we report a photoacoustic-imaging nanomotor, PPIC, which addresses these challenges through integrated functions of oxygen production, deep tissue penetration and photoacoustic imaging.
View Article and Find Full Text PDFUnraveling complex karyotype clonal architecture: co-existing double TP53 mutations alongside DNMT3A, TET2, and NF1 mutations - a case study.
Cancer Genet
August 2025
Clinical Hematology and BMT Unit, Bahrain Oncology Center, Road 2835, Block 228, P.O. Box 24343, Busaiteen, Kingdom of Bahrain. Electronic address:
Complex chromosomal changes in Acute Myeloid Leukemia (AML) are highly heterogeneous, with disease progression shaped by both the number and nature of abnormalities. Rarely do, multiple unrelated clones with independent chromosomal changes coexist at diagnosis. Present study showcases a comprehensive characterization of two cytogenetically distinct complex clones in AML, driven by non-cyclic and chromoplexy mechanisms, highlighting their co-existence with key molecular alterations (TP53, NF1, DNMT3A, TET2) along with their potential contribution to clonal evolution.
View Article and Find Full Text PDFRelative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference.
Int J Clin Oncol
September 2025
Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan.
Background: Limited data are available on relative survival (RS) among cancer survivors enrolled in private cancer insurance in Japan. Additionally, the incidence of second primary cancers or recurrences, as applicable, after a certain period remains unclear.
Methods: We analyzed 8,846 cancer survivors, including carcinoma in situ, aged 15-79 years, enrolled in private cancer insurance between April 2005 and September 2021, and diagnosed before April 2022.
An unusual spindle cell variant of papillary thyroid carcinoma with KIF5B::MET fusion: report of a case.
Virchows Arch
September 2025
Ningbo Clinical Pathology Diagnosis Center, #685 Huancheng North Road, Ningbo, Zhejiang, 315000, China.
The spindle cell variant of papillary thyroid carcinoma (PTC) is exceptionally rare and poses significant diagnostic challenges due to its morphological overlap with other spindle cell lesions of the thyroid. We report a novel case of spindle cell variant PTC in a 66-year-old woman presenting with a TI-RADS 4 thyroid nodule, initially classified as Bethesda III on fine-needle aspiration. Histopathological examination revealed a biphasic tumor composed predominantly of bland spindle cells arranged in solid sheets and fascicles, admixed with entrapped thyroid follicles.
View Article and Find Full Text PDF